Veraguensin

CAS No. 19950-55-1

Veraguensin( —— )

Catalog No. M29056 CAS No. 19950-55-1

Veraguensin is derived from Magnolia sp.. Veraguensin inhibits bone resorption and shows high antileishmanial activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 180 In Stock
10MG 297 In Stock
25MG 502 In Stock
50MG 699 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Veraguensin
  • Note
    Research use only, not for human use.
  • Brief Description
    Veraguensin is derived from Magnolia sp.. Veraguensin inhibits bone resorption and shows high antileishmanial activity.
  • Description
    Veraguensin is derived from Magnolia sp.. Veraguensin inhibits bone resorption and shows high antileishmanial activity.(In Vitro):Veraguensin shows activity against trypomastigote T. cruzi.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    19950-55-1
  • Formula Weight
    372.461
  • Molecular Formula
    C22H28O5
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (67.12 mM)
  • SMILES
    COc1ccc(cc1OC)[C@H]1O[C@H]([C@@H](C)[C@@H]1C)c1ccc(OC)c(OC)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • p38 MAP Kinase Inhib...

    p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.

  • dencichine

    Dencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.

  • PH797804

    PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.